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Abstract 
CDC7 is a serine-threonine kinase that participates 
in multiple cellular processes, including DNA 
replication, chromosomal segregation, S phase cell 
cycle progression, and DNA damage checkpoint. 
CDC7 is frequently highly expressed in several types 
of neoplasm, and it has been associated with cancer 
development and poor clinical outcomes. In different 
cancer models, functional studies indicated that 
CDC7 may be an attractive target for antineoplastic 
therapy, and CDC7 inhibitors have been developed. 
The present review on CDC7 contains data on 
DNA/RNA, the protein encoded, and the implication 
of this gene in cancer cell biology and clinical 
outcomes. 
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Identity 
Other names: Hsk1, CDC7L1, HsCDC7, huCDC7 
HGNC (Hugo): CDC7 
Location: 1p22.1 
DNA/RNA 
Description 
The entire CDC7 gene is approximately 24.9 Kb 
(start: 91500851 and end: 91525764 bp; orientation: 
Plus strand). On the NCBI database 
(https://www.ncbi.nlm.nih.gov/gene), there are 3 
transcript variants (exons: 12, coding exons: 11) for 
CDC7 that encode for the same protein (574 amino  
acids [aa]): the transcript variant 1 represents the 
most commonly occurring transcript (transcript 
length: 3215 bp); the transcript variant 2 presents a 
different splice site in the 5' UTR (transcript length: 
3188 bp), while the transcript variant 3 has different 
segment for part of its 5' UTR (transcript length: 
3316 bp).  
On the Ensembl database 
(http://www.ensembl.org/), there are 3 additional 
transcript variants for CDC7: one transcript variant 
has 6 exons (5 coding exons), length of 701 bp, and 
encode a 157 aa protein, and two transcript variant 
that encodes no protein (one with 4 exons and length 
of 729 bp, and other with 4 exons and length of 594 
bp). 
Protein 
Figure 1. Schematic structure of CDC7 protein. (A) The 
CDC7 protein presents 574 aa and contains a protein 
kinase domain that is responsible for its activity. The 
position of amino acids is indicated in the Figure. The 3D 
reconstitution of CDC7 protein was constructed using 
Swiss-model platform (https://swissmodel.expasy.org/), and 
cartoon (B) and surface (C) versions of the protein are 
illustrated. 
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Figure 2. CDC7-mediated cell signaling and cellular processes. (A) CDC7 binds to DBF4 (activated complex), which acts in 
initiation of DNA replication at origins by phosphorylation of MCM (mini-chromosome maintenance) proteins.  (B) Upon DNA 
damage or stress, CDC7 phosphorylates claspin and activates ATR/CHK1 pathway.  (C) CDC7 phosphorylates HP1 that 
promotes cohesion of sister chromatids in mitosis. 
 
Description 
CDC7 protein consists of 574 aminoacids (aa) with 
a molecular weight of 64 kDa and has a conserved 
protein kinase domain (58-574 aa) in the C-terminal 
region. The schematic representation of the CDC7 
protein is illustrated in Figure 1. 
Expression 
Ubiquitous. 
Localisation 
Nucleoplasm, cytokinetic bridge, and mitotic 
spindle. 
Function 
CDC7 is a serine-threonine kinase that participates 
in chromosomal DNA replication promoting 
progression of S phase of the cell cycle, normal 
chromosomal segregation during mitosis, and 
checkpoint response to DNA damage (Bousset and 
Diffley, 1998; Sawa and Masai, 2009; Takahashi et 
al., 2008). During DNA synthesis, CDC7 forms a 
complex with DBF4 (CDC7/DBF4 complex, also 
known as DDK), which acts in initiation of DNA 
replication at origins by phosphorylation of MCM 
(mini-chromosome maintenance) proteins 
(important components of replicative helicase), and 
allowing replisome activity (Kim et al., 2003b; 
Labib, 2010; Matsumoto and Masai, 2013; Sclafani 
and Hesselberth, 2018). Regarding chromosomal 
segregation, CDC7 regulates multiple proteins that 
enable cohesin deposition on DNA (Takahashi et al., 
2008) and phosphorylates HP1 that promotes 
cohesion of sister chromatids in mitosis (Bailis et al., 
2003). In addition, it has been described as a relevant 
role for CDC7 in the monopolar attachment to 
kinetochores during meiosis (Matos et al., 2008). In 
checkpoint response to DNA damage, CDC7 is 
important for ATR - CHK1 activation by 
phosphorylation of CLSPN (claspin) (Kim et al., 
2008; Rainey et al., 2013; Tenca et al., 2007), which 
leads to inactivation of the anaphase-promoting 
complex (Yamada et al., 2013). It has been 
demonstrated that DBF4 are upstream targets of 
ATM or ATR, and once phosphorylated activates 
intra-S phase checkpoint, which suppresses DNA 
replication under stress (Lee et al., 2012). Under high 
replication stress, CDC7 may trigger apoptosis by 
CHK1-dependent pathway (Costanzo et al., 2003; 
Tsuji et al., 2008). The main cellular and molecular 
functions of CDC7 are illustrated in Figure 2. 
Homology 
The CDC7 gene and protein are highly homologous 
among different species, as shown in Table 1.  
% Identity for: Homo 
sapiens CDC7 
Symbol Protein DNA 
vs. P.troglodytes CDC7 97.7 98.6 
vs. M.mulatta CDC7 96.9 97.8 
vs. C.lupus CDC7 90.6 92.9 
vs. B.taurus CDC7 89.4 90.8 
vs. M.musculus Cdc7 81.4 83.2 
vs. R.norvegicus Cdc7 81.5 81.9 
vs. G.gallus CDC7 69.8 74.1 
vs. X.tropicalis cdc7 66.9 68.3 
vs. D.rerio cdc7 63.7 60.6 
vs. A.gambiae AgaP_AGAP002110 40.0 43.8 
Table 1. Comparative identity of human CDC7 with other 
species (Source: http://www.ncbi.nlm.nih.gov/homologene) 
Mutations 
Somatic 
A total of 272 unique samples presenting CDC7 
mutations were found among the 36154 tested 
samples reported in COSMIC (Catalogue of Somatic 
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Mutations in Cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic). The mutations p.N31Tfs*51 ([c.92del] large 
intestine, n=16; stomach, n=4; lung, n=1; and biliary 
tract, n=1) and p.L28* ([c.83T>A], liver, n=4; 
prostate, n=3; skin, n=3; lung, n=2; soft tissue, n=1; 
and glioma, n=1) were the most frequent. In 
agreement, 315 out of 46651 (0.7%) tested samples 
presented CDC7 genetic alterations (mutations, 
amplifications, deep deletions, and multiple 
alterations), as reported in cBioPortal 
(http://www.cbioportal.org). The distribution of 
somatic mutations was 122 missense substitutions, 
51 truncating, 1 inframe, and 2 other mutations (a 
total of 176 mutated samples [0.4%]). Interestingly, 
p.N31Tfs*51 mutation was observed in 15 out of 
176 mutations in stomach adenocarcinoma, uterine 
endometrioid carcinoma, colon cancer, and others. 
Indeed, somatic mutations in CDC7 have been 
reported in colorectal and gastric cancer, but its 
biological relevance is still poorly elucidated 
(Greenman et al., 2007). 
Implicated in 
Adrenocortical carcinoma 
Data mining of gene expression revealed positive 
regulation of genes involved in DNA damage and 
cell cycle pathways in samples from adrenocortical 
carcinoma patients, including CDC7, their higher 
levels were associated with worse overall survival 
(Subramanian and Cohen, 2019). 
Bladder cancer 
In order to identify candidate genes associated with 
cisplatin-resistant bladder cancer cells, sensitive and 
cisplatin-resistant cell lines were used for microarray 
analysis to determine the differential expression of 
significant genes in resistance. A total of 18 genes, 
including CDC7, were significantly upregulated in 
cisplatin-resistant cell lines (Kim et al., 2016). 
Breast Cancer 
In breast cancer, high CDC7 expression had been 
reported (Bonte et al., 2008; Zografos et al., 2019), 
and associated with the development of aggressive 
disease, including ERBB2 (HER2) overexpression, 
triple-negative subtypes, accelerated cell cycle 
progression, disrupted tumor differentiation, 
genomic instability, increased NPI score, and 
reduced disease-free survival (Rodriguez-Acebes et 
al., 2010). Using tissue microarray of a cohort of 
2197 highly characterized breast carcinomas, CDC7 
expression was found in 1088 samples (57%), of 
which 228 samples exhibited moderate or strong 
expression. High CDC7 levels were also related to 
medullary histotype, high tumor grade, estrogen 
receptor-negative status, high Ki67 expression; 
overexpression of TP53 and CDKN2A; and 
amplification of HER2, MYC, MDM2, CCND1, and 
ESR1, unfavorable tumor phenotype, and poor 
prognosis (Choschzick et al., 2010).  
In triple negative breast cancer cellular models, the 
dual CDC7/CDK9 inhibitor (PHA-767491) 
synergizes with tyrosine kinase inhibitors to 
overcome resistance to EGFR -targeted therapy 
(McLaughlin et al., 2019): combined inhibition of 
EGFR and CDC7/CDK9 reduced cell proliferation 
accompanied by apoptosis induction, G2/M cell 
cycle arrest, and DNA replication inhibition.  
Due to the rarity of male breast cancer (MBC), serum 
protein alterations have not been extensively studied. 
Using two-dimensional gel electrophoresis (2-DE) 
and matrix-assisted laser desorption/ionization time 
mass spectrometry (MALDI-TOF MS), a panel of 
differentially expressed serum proteins were 
identified, which included the high CDC7 
expression in MBC patients (Zografos et al., 2019). 
Clear cell renal cell carcinoma 
Ghatalia et al. (Ghatalia et al., 2016) analyzed the 
gene expression of kinases paired samples from 
primary and metastatic tumor tissues and found that 
CDC7 is more expressed in metastatic tumors. Using 
the Cancer Genome Atlas (TCGA) data, the authors 
also observed an association between high CDC7 
expression and reduced metastasis-free survival 
(Ghatalia et al., 2016). DISEASE 
Cervical intraepithelial neoplasia 
Using microarray analysis, CDC7 was found among 
highly expressed genes in high-grade squamous 
cervical intraepithelial lesions (Suman and Mishra, 
2018). 
Colorectal cancer 
Bonte et al. (Bonte et al., 2008) reported a high 
CDC7 expression in 8 of out 10 cases of colorectal 
cancer. In agreement, Chen et al. (Chen et al., 2013) 
reported a significantly higher CDC7 mRNA and 
protein expression in samples from 39 colorectal 
patients compared to their tumor-adjacent normal 
colorectal tissues. Analysis of 1800 colorectal 
carcinomas, by immunohistochemistry and tissue 
microarray, showed that CDC7 was highly 
expressed. Of note, CDC7 expression was 
significantly associated with TP53, suggesting that 
CDC7 may be a potential target in a subset of tumors 
with high TP53 expression (Melling et al., 2015). In 
contrast, loss of CDC7 expression was significantly 
associated with high tumor stage and grade, but was 
not related to nodal status. In multivariate survival 
analysis, strong CDC7 expression was an 
independent marker of improved patient survival 
(Melling et al., 2015). 
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Esophageal squamous cell 
carcinoma 
CDC7 is highly expressed in esophageal squamous 
cell carcinoma (ESCC) tissues, and that CDC7 
knockdown inhibits cell proliferation, migration, and 
invasion, and induces apoptosis in ESCC cells. In 
addition, downregulation of CDC7 also partially 
enhances the chemosensitivity of ESCC cells to 
cisplatin and 5-fluorouracil, indicating that CDC7 
may serve as a potential therapeutic target in ESCC 
(Cao and Lu, 2019). 
Glioblastoma 
Inhibition of CDC7 by inhibitor PHA-767491 
significantly reduced cell viability, proliferation, 
migration, invasion, and tumorigenesis, and induced 
apoptosis in glioblastoma models (Erbayraktar et al., 
2016; Li et al., 2018).  
Li et al. (Li et al., 2018) identified that CDC7 
expression was enhanced and functionally necessary 
for proliferation in glioblastomas, and its high 
expression was associated with poor prognosis. 
Head and neck squamous cell 
carcinoma 
Human papillomavirus (HPV) is associated with a 
subset of head and neck squamous cell carcinoma 
(HNSCC) that can harbor HPV DNA and it was 
suggestive that there are biological and clinical 
differences between HPV positive (HPV +) and 
negative (HPV -) HNSCC. Slebos et al. (Slebos et 
al., 2006), comparing gene expression profiles of 
HPV+ and HPV- tumors, found 91 genes 
differentially expressed, including high CDC7 
expression in HPV+ HNSCC. 
Hematological neoplasms 
Hess and colleagues (Hess et al., 1998) identified the 
sequence of encoding human gene CDC7 and 
reported its overexpression in several types of 
cancers, including hematological neoplasms. 
Latterly, it was confirmed by Bont et al. (Bonte et 
al., 2008) in additional leukemia cellular models.  
In chronic lymphocytic leukemia (CLL), CDC7 was 
expressed and activated in lymph node biopsies.  
A similar finding was also observed in an in vitro 
model that partially recapitulates lymph node 
proliferation centers of CLL.  
These data suggested a potential role for CDC7 in 
the aberrant lymph node microenvironment (Natoni 
et al., 2011).  
In addition, high CDC7 expression was associated 
with poor prognosis in patients with diffuse large B-
cell lymphoma (DLBCL) (Hou et al., 2012b; Hou et 
al., 2011; Krawczyk et al., 2009). In DLBCL cell 
lines, CDC7 silencing combined with rituximab 
synergistically increased apoptosis (Hou et al., 
2012a).  
The dual CDC7/ CDK9 inhibitor, PHA-767491, also 
induced cell death on a panel of multiple myeloma 
cell lines and primary patient samples alone or in 
combination with drugs currently used in the clinics, 
including the TP53 mutant cells that developed 
resistance to dexamethasone, melphalan, and 
doxorubicin. PHA-767491 had the same effect on 
primary myeloma cells from patients who relapsed 
with progressive refractory disease. These data 
suggested that the mechanisms leading to 
chemoresistance in myeloma may not affect the 
activity of a dual CDC7/CDK9 inhibitor, thus 
supporting further evaluation of CDC7 and CDK9 
targeting in multiple myeloma (Natoni et al., 2013).  
In acute myeloid leukemia (AML), the dual 
CDC7/CDK9 inhibitor, PHA-767491, 
downregulated MCL1 and sensitized AML cell lines 
and primary AML blasts to BCL2 inhibitors, ABT-
737 and ABT-199 (O' Reilly et al., 2018). 
Hepatocellular carcinoma 
Using gene expression data sets, Zhuang et al. 
(Zhuang et al., 2018) detected that expression of 
various genes, including CDC7, was increased in 
hepatocellular carcinoma tissues compared to 
adjacent normal tissues. CDC7 overexpression was 
correlated with advanced histological grade and/or 
vascular invasion, and predicted worse overall and 
disease-free survival in hepatocellular carcinoma 
patients (Zhuang et al., 2018). It is important to 
highlight that the CDC7 inhibitor (PHA-767491) had 
a synergistic antitumor effect with 5-FU, exhibiting 
stronger cytotoxicity and inducing significant 
apoptosis in hepatocellular carcinoma cell lines and 
xenograft models (Li et al., 2015). 
Lung cancer 
In non-small lung cancer (NSCLC) cell lines and 
tissue samples, CDC7 expression was highly 
expressed (Bonte et al., 2008). In agreement, CDC7 
was significantly increased in lung adenocarcinoma 
tissues, as observed by immunohistochemistry and 
gene expression analysis in lung adenocarcinoma 
(Cao, 2019). In another study, high CDC7 
expression significantly correlates with TP53 
mutational status and predicts poor clinical outcomes 
in lung adenocarcinoma patients. In an experimental 
lung cancer model, CDC7 was also upregulated by 
gain-of-function mutant TP53, which induced cell 
cycle progression and tumorigenesis (Datta et al., 
2017). 
Melanoma 
CDC7 gene is located at chromosome 1p22 band, 
which was identified as a melanoma susceptibility 
locus with the high frequency of loss of 
heterozygosity (Walker et al., 2004).  
In a series of benign and dysplastic nevi, primary 
cutaneous melanomas and melanoma cutaneous 
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metastasis samples, CDC7 regulatory subunits, 
DBF4, were found to be upregulated in malignant 
tissues (Nambiar et al., 2007), which was associated 
with shorter relapse-free survival.  
In the same study, DBF4 depletion reduced 
melanoma cell survival and proliferation (Nambiar 
et al., 2007).  
Clarke and colleagues (Clarke et al., 2009), using a 
tissue microarray containing 40 melanomas, 40 Spitz 
tumors, and 30 nevi reported that invasive 
melanomas and atypical Spitz nevi exhibited the 
highest CDC7 expression.  
In order to better understand the transcriptional 
regulation cell cycle checkpoints in melanocytes and 
melanoma cell lines, Kaufmann et al. (Kaufmann et 
al., 2008) analyzed global gene expression patterns 
upon DNA damage induced by ionizing radiation, 
and most melanoma cell lines (11 of out 16) showed 
significant defects in checkpoints, which included 
reduced expression of TP53 transcriptional targets, 
and enhanced expression of proliferation-associated 
genes. Of note, defective melanomas at checkpoint 
G1 exhibited higher levels of DNA synthesis-related 
genes, including CDC7 and CKS1B.  
Using a VSV-cDNA library and B16 melanoma 
tumors, CDC7 was identified (among others) as a 
potential immunogenic antigen for chemotherapy or 
immunotherapy (Zaidi et al., 2015). 
Oral squamous cell carcinoma 
Evaluating CDC7 protein expression, by 
immunohistochemistry, in a cohort of 105 oral 
squamous cell carcinoma (OSCC) tumors and 30 
benign oral tissues, CDC7 overexpression was found 
in 91% of tumor cases and 1% benign cases (Cheng 
et al., 2013). In multivariate analysis, CDC7 was an 
independent marker for overall survival in a cohort 
of 80 OSCC patients.  
In OSCC cell lines, overexpression of CDC7 
inhibited genotoxin-induced apoptosis, suggesting 
that high CDC7 expression increases chemotherapy 
resistance (Cheng et al., 2013).  
Yong-Deok and colleagues (Yong-Deok et al., 2015) 
investigated the expression of inflammation-
associated genes in samples from tumor and normal 
tissue from OSCC patients, in which genetic analysis 
of functional networks and ontologies identified 
CDC7 as one of the relevant genes. Pharmacological 
CDC7 inhibition with XL413 markedly reduced cell 
viability and proliferation by induction of apoptosis 
in OSCC cell lines (Jin et al., 2018). 
Osteosarcoma 
In order to screen for key osteosarcoma biomarkers, 
Liu et al. (Liu et al., 2016) systematically screened 
mRNA and proteins differently expressed, and 
CDC7 was found as part of a gene signature for 
osteosarcoma. 
Ovarian carcinoma 
CDC7 was a strong independent prognostic marker 
in epithelial ovarian carcinoma and CDC7 targeted 
inhibition leads to specific tumor cell death. In a 
cohort of 143 cases of ovarian cancer, increased 
levels of CDC7 protein were significantly associated 
with reduced tumor differentiation, advanced 
clinical stage, genomic instability, and accelerated 
cell cycle progression (Kulkarni et al., 2009). 
Moreover, CDC7 predicted disease-free survival, 
regardless of age, tumor grade and stage. CDC7 
downregulation by siRNA in ovarian cancer cells 
(SKOV-3 and Caov-3) resulted in high levels of 
apoptosis (Kulkarni et al., 2009). 
Pancreatic cancer 
In a cohort of 73 pancreatic adenocarcinoma 
patients, including 24 controls, CDC7 was highly 
expressed in pancreatic adenocarcinoma compared 
to benign pancreatic tissue, as observed by 
immunohistochemistry (Huggett et al., 2016). CDC7 
depletion using siRNA and PHA-76749, a CDC7 
small molecule inhibitor, in pancreatic cancer 
cellular models (Capan-1 and PANC-1), resulted in 
marked apoptotic cell death. Using human 
pancreatic cell lines (Capan-1, BxPC3, and PANC-
1), the preclinical efficacy of another CDC7 
inhibitor, MSK-777, was reported (induction of cell 
cycle arrest in G1/S and apoptosis) (Skoura et al., 
2013). Taken together, these results indicated that 
CDC7 is a potential target and may be used as a 
complementary diagnosis marker to predict 
responses in pancreatic adenocarcinoma. 
Papillary thyroid carcinoma 
Fluge et al. (Fluge et al., 2006) studied gene 
expression profile using cDNA microarray in 
papillary thyroid carcinoma samples, including 7 
clinically aggressive carcinomas, 10 differentiated 
thyroid papillary carcinomas, and normal thyroid 
tissues, which were confirmed by RT-PCR, in situ 
hybridization and immunohistochemistry. Patients 
with aggressive and poorly differentiated thyroid 
carcinoma were specifically characterized by the 
marked positive regulation of several genes related 
to cell proliferation, including CDC7 (Fluge et al., 
2006). 
Salivary gland tumor 
Jaafari-Ashkavandi et al. (Jaafari-Ashkavandi et al., 
2019) reported high CDC7 expression in malignant 
salivary gland tumors compared to pleomorphic 
adenomas, and its positive correlation with tumor 
differentiation in samples from 15 cystic adenoid 
carcinomas, 12 mucoepidermoid carcinomas, 14 
pleomorphic adenomas, and 5 normal salivary 
glands (total 46 patients and donors). 
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Uterine leiomyosarcoma 
Barlin and colleagues (Barlin et al., 2015) compared 
the molecular profiles of 23 samples of uterine 
leiomyosarcoma (ULMS) and 29 samples of normal 
myometrium (NL) to identify clinically relevant 
molecular subtypes. Pathway analyses of genes 
differentially expressed between ULMS and NL 
samples identified over-representation of cell cycle 
regulation, DNA repair, and genomic integrity. 
External validation confirmed differential 
expression in 31 genes, with 84% overexpressed 
genes, including CDC7 and other cell cycle 
regulators (Barlin et al., 2015). 
To be noted 
Cdc7-deficient mice present embryonic lethality at 
day 3.5 (Kim et al., 2002). Mice carrying Cdc7 
hypomorphic allele (Cdc7-/-tg) were born apparently 
normal, but smaller than their littermates. However, 
the rate of mortality during postnatal development 
was 75% within 3 days postpartum. Surviving Cdc7-
/tg mice presented a normal life span and body 
growth retardation compared to their littermates. In 
addition, male and female Cdc7-/tg mice had 
impaired spermatogenesis and abnormal oogenesis, 
respectively (Kim et al., 2003a).  
Promising results of CDC7 inhibition in cancer 
models drawn attention for the development of 
selective pharmacological inhibitors, among which 
can be mentioned 89S (Menichincheri et al., 2009), 
PHA-767491 (Natoni et al., 2011), 1H-pyrrolo[2,3-
b]pyridine derivatives (Ermoli et al., 2009), 3-
aminopyrimidine analog, pyrrolopyridinone analog, 
tricyclic CDC7 inhibitor, indazolylpyrimidin-2(1H)-
one inhibitor, thienopyrazole-base inhibitor, 2-
pyrimidyl-5-amidothiophene, imidazolone-based 
inhibitor (Sawa and Masai, 2009), NMS-1116354 
(Colotta et al., 2010), TAK-931 (Iwai et al., 2019; 
Kurasawa et al., 2020), and XL413 (Koltun et al., 
2012). The main cellular effects triggered by CDC7 
inhibitors in the neoplasm models are: the late S-
phase progression, reduced cell proliferation, DNA 
damage checkpoint activation, and apoptosis (Iwai et 
al., 2019; Kurasawa et al., 2020; Sawa and Masai, 
2009). Clinical studies using CDC7 inhibitors, 
NMS-1116354 and TAK-931, in patients with solid 
tumors have been conducted, but the results of the 
clinical outcomes have not yet been published 
(https://clinicaltrials.gov/).  
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